Packaging for Pharma Products in India: What Manufacturers and Distributors Must Know

India occupies a unique position in the global pharmaceutical supply chain. The country accounts for approximately 20% of global generic medicine exports by volume, supplying over 200 countries, and received over 1,800 USFDA drug approvals between 2022 and 2024, the highest outside the United States. This scale creates an equally large demand for packaging that is not just functional, but verifiably compliant with domestic and international regulatory standards.

The India pharmaceutical packaging market was valued at USD 5.14 billion in 2025 and is forecast to reach USD 7.81 billion by 2030, growing at a CAGR of 8.72%. Within that, flexible packaging formats including pouches, sachets, and laminated bags are growing faster than rigid formats, driven by their barrier performance, cost efficiency, and suitability for bulk institutional supply, ORS formats, nutraceuticals, and export packaging.

This guide covers what pharma manufacturers and distributors in India need to know about flexible pharmaceutical packaging pouches: the regulatory framework, how ICH Zone IVb drives material selection, which pouch formats work for which pharmaceutical applications, how to read barrier specifications, and what a compliance-ready packaging checklist looks like.

Note: This guide provides a practical overview of pharmaceutical packaging requirements in India as of June 2026. Regulations, schedules, and compliance timelines are subject to revision by CDSCO, the Ministry of Health, and other bodies. Verify current requirements with your regulatory consultant before commercial launch.

Why Pharmaceutical Packaging Is a Compliance Decision, Not Just a Cost Decision

In most product categories, packaging is primarily a commercial and logistical decision: what protects the product, what fits the budget, what looks right on shelf. In pharmaceuticals, it is a regulatory and patient safety decision first. The packaging is the last physical barrier between the drug formulation and the conditions that degrade it. If that barrier fails, the product fails.

The consequences of packaging failure in pharma are severe: moisture ingress can hydrolyse active pharmaceutical ingredients, reducing potency and generating degradation products. Oxygen ingress can trigger oxidation. Light exposure can photodegrade photosensitive compounds. Contamination from packaging materials themselves, through migration of plasticisers, inks, or adhesives, can create safety issues that trigger CDSCO enforcement and product recall.

For Indian manufacturers exporting to regulated markets, the stakes are higher still. Regulated market shipments, including exports to the US, EU, and UK, mandate stringent packaging standards including tamper-evident closures, child-resistant designs, and serialisation, and USFDA 483 observations related to packaging have resulted in import alerts that block entire manufacturing facilities from the US market. Packaging compliance is not a secondary consideration: it is a market access requirement.

The ICH Zone IVb Requirement: Why India's Climate Makes Packaging Harder

The International Council for Harmonisation (ICH) divides the world into four climatic zones based on mean kinetic temperature and relative humidity. India falls in Zone IVb: the most demanding zone, specified at 40°C mean kinetic temperature and 75% relative humidity. This is the condition under which all pharmaceutical products sold in India must be tested for stability.

What this means practically: every pharmaceutical formulation launched in India must be validated in stability studies conducted at 40C/75% RH conditions (accelerated, 6 months) and 30C/65% RH (intermediate, 12 months). The packaging used in those studies must maintain its barrier properties throughout. If moisture permeation through the packaging causes the active ingredient to degrade beyond specification during stability testing, the packaging has failed the regulatory test, regardless of how cost-effective or well-intentioned it was.

Packaging that passes stability testing at Zone IVb conditions is not just a compliance box to tick. It is the fundamental proof that the drug will retain its stated potency and safety profile throughout its shelf life in Indian conditions, including storage at distributors, pharmacies, and in patients' homes without air conditioning.

The ICH Zone IVb requirement makes moisture barrier performance the primary technical specification for any pharmaceutical packaging material used in India. WVTR (Water Vapour Transmission Rate) and OTR (Oxygen Transmission Rate) are the two quantitative measures that determine whether a laminate film is adequate for a given formulation's shelf life target. For a deeper explanation of WVTR and moisture barrier concepts in flexible packaging, see our guide to moisture-proof packaging for food and pharma products in India.

Pouch Formats for Pharmaceutical Applications: A Selection Guide

Different pharmaceutical product categories and distribution models require different pouch formats. The common requirement across all of them is that the inner sealant layer must be pharmaceutical-grade and the laminate structure must meet the WVTR and OTR specifications for the formulation.

Material Structures: How to Read a Pharma Pouch Laminate

A pharmaceutical pouch is not a single material: it is a multi-layer laminate where each layer serves a specific function. Understanding the laminate structure helps manufacturers specify the right barrier performance and allows distributors to verify supplier claims.

Always request the WVTR and OTR data sheet from your supplier for any laminate you intend to use in pharmaceutical packaging. A supplier who cannot provide this data is a supplier whose material should not be used for pharma applications.

The same barrier principles that apply to pharmaceutical pouches apply to food packaging for moisture-sensitive products. For a practical explanation of how WVTR, OTR, and multi-layer laminate structures work together in flexible packaging, see our guide to moisture-proof packaging pouches.

Three Side Seal Pouches for Pharmaceutical Use

The three side seal pouch is the most widely used flexible pouch format in Indian pharmaceutical packaging for non-blister applications. It is sealed along three factory edges during manufacture, filled through the open top, and heat-sealed after filling. The result is four independent seal lines with the top heat seal providing the tamper-evident closure.

Why Three Side Seal Works for Pharma

• Multiple seal lines:  Four independent seals (three factory seals and one fill-and-seal top). Even under Zone IVb storage conditions, the multiple seal redundancy significantly reduces the probability of moisture ingress through seal failure.

• Heat-sealed tamper evidence:  The top heat seal is destructive on first opening: it cannot be resealed without visible evidence of tamper. This meets CDSCO tamper-evidence requirements for OTC and institutional supply formats.

• Full print surface:  Both front and back panels are available for mandatory labelling, dosage instructions, Schedule H/H1 warnings, and batch traceability information, without reducing structural integrity.

• Compatible with all fill weights:  Three side seal pouches scale from 5g unit-dose sachets to 500g bulk institutional packs, making them viable across the full range of pharmaceutical distribution formats.

• Zipper option for multi-dose:  For products dispensed across multiple uses, a press-to-close zipper can be integrated below the heat seal. The consumer tears above the zipper to break the tamper-evident seal, then uses the zipper for subsequent access. This design satisfies both tamper evidence and consumer convenience requirements.

Browse Three Side Seal Pouches: ongomart.com/three-side-seal-pouch-manufacturer

For a full explanation of three side seal construction, closure types, and material variants, see our guide to packaging for dry fruits and nuts using three side seal pouches, which covers the format in detail with the same barrier and moisture protection principles applicable to pharmaceutical use.

Stand Up Pouches for Bulk Pharmaceutical Supply

For bulk institutional pharmaceutical supply, hospital dispensing, and larger retail pack sizes of nutraceuticals and health supplements, stand up pouches (SUP) offer advantages that flat three side seal pouches do not: they stand upright independently, display labelling on a larger panel, and are easier for institutional users to handle and dispense from.

Foil stand up pouches (PET/AL/PE):  Maximum barrier performance in a stand-up format. Used for bulk supply of moisture-sensitive formulations to hospitals, dispensaries, and institutional buyers. Available with resealable zipper for multi-access dispensing.

Kraft stand up pouches with foil liner:  For nutraceuticals, ayurvedic formulations, and D2C health brands where natural aesthetic and premium barrier performance are both required. The kraft outer layer communicates clean, natural positioning while the inner foil lining provides Zone IVb-compatible moisture protection.

Transparent stand up pouches:  For nutraceuticals, ORS formulations, and health supplements where product visibility is important and the formulation is not highly moisture-sensitive. Food-grade film with resealable zipper.

Browse Stand Up Pouches: ongomart.com/standup-pouch-sup-manufacturer

CDSCO Labelling Requirements for Pharmaceutical Pouches

All pharmaceutical packaging in India must comply with labelling requirements under Rule 96 of the Drugs and Cosmetics Rules 1945, as enforced by CDSCO. Compliance is mandatory regardless of whether the product is prescription or OTC, branded or generic, domestic or export.

Mandatory label elements under Rule 96:  

• Drug name (brand name and generic/INN name)

• Active ingredient composition (quantity per unit dose)

• Name and address of manufacturer, with manufacturing licence number

• Batch number and date of manufacture

• Expiry date in clear, uncoded format (Month/Year minimum)

• Net quantity (weight, volume, or number of units)

• Storage conditions (temperature, humidity, light exposure)

• Schedule H, H1, or X designation and associated warnings where applicable

• Retail price (MRP) inclusive of all taxes for domestic market products

From 2025, QR codes for traceability are mandatory for Schedule H, H1, and X drugs across all packaging levels, including primary flexible packaging. The QR code must encode unique batch and product identifiers sufficient for supply chain traceability.

For export to regulated markets, additional labelling requirements apply per USFDA 21 CFR 201 (US), EU Directive 2001/83/EC (Europe), and equivalent frameworks. Export packaging must be validated separately from domestic packaging even if the same pouch structure is used.

Tamper-Evident Packaging: What Pharma Regulations Require

Tamper-evident packaging is required for all OTC pharmaceutical products and is strongly recommended for institutional and prescription supply formats as well. CDSCO guidelines under Schedule M reinforce this requirement, and export to regulated markets makes it mandatory regardless of dosage form.

For flexible pouches: a heat-sealed top that can only be opened by tearing meets the tamper-evident requirement. The tear is destructive and visible: once opened, the pouch cannot be resealed without evidence of access. A zipper-only closure does not meet this standard because it can be opened and resealed without visible evidence of tampering.

The compliant design for multi-dose pharmaceutical pouches is a dual closure: heat seal above, zipper below. The consumer tears above the zipper to break the tamper-evident heat seal on first use, then uses the zipper for all subsequent access. This configuration satisfies both tamper evidence (first opening) and patient convenience (subsequent openings) simultaneously.

If your pharmaceutical pouch uses only a zipper closure without a heat seal above it, it is not tamper-evident and does not meet CDSCO requirements for OTC products. Add a heat seal above the zipper line during filling and sealing to achieve compliance.

EPR Compliance for Pharmaceutical Flexible Packaging

Pharmaceutical manufacturers using plastic flexible packaging, including three side seal pouches, sachets, and stand up pouches, carry Extended Producer Responsibility obligations under India's Plastic Waste Management Rules.

Registration on the CPCB EPR portal is mandatory, and annual recycling targets must be met through EPR certificates procured from registered recyclers.

From July 2025, all plastic pharmaceutical packaging must carry a QR code or barcode incorporating the CPCB EPR registration number, in addition to the traceability QR code required by CDSCO for Schedule H, H1, and X drugs. These are two distinct QR code requirements from two different regulatory bodies, and both must appear on the pack. For a complete breakdown of EPR obligations for manufacturers, see our guide to EPR compliance for ecommerce packaging in India.

A Compliance Checklist for Pharmaceutical Pouch Packaging

Use this checklist when sourcing flexible pouches for pharmaceutical applications in India:

OnGoMart Pharmaceutical Packaging Pouches

OnGoMart supplies food-grade and pharma-suitable flexible pouches for pharmaceutical manufacturers, nutraceutical brands, health supplement companies, and institutional distributors across India. All pouches are BPA-free and available in bulk with B2B pricing and Pan India delivery.

Three Side Seal Pouches  -- available in foil laminate (PET/AL/PE) and transparent variants. Three factory-sealed edges plus heat-seal top for tamper evidence. Suitable for tablets, capsules, powders, ORS sachets, and nutraceuticals. Zipper option available for multi-dose formats.

Stand Up Pouches  -- foil laminate, kraft with foil liner, and transparent variants. Resealable zipper. Suitable for bulk institutional supply, 100g to 1 kg pharmaceutical and nutraceutical packs, and D2C health brand retail formats.

Self Lock Pouches  -- press-to-close zipper, food-grade BPA-free film. Suitable for tablet strips, capsule retail packs, OTC health products, and nutraceutical accessories requiring clean resealable packaging.

Browse all packaging: ongomart.com

FAQ: Pharmaceutical Packaging Pouches India

Q: What packaging is used for pharmaceutical tablets and capsules in India?

Blister packs are the dominant format for unit-dose retail tablets and capsules. For bulk institutional supply, clinical trials, and hospital dispensing, three side seal pouches and stand up pouches made from foil-laminated film (PET/AL/PE) are standard. For nutraceuticals and health supplements, transparent or kraft three side seal pouches with zipper closures are widely used.

Q: What is ICH Zone IVb and why does it matter for pharma packaging in India?

ICH Zone IVb specifies stability testing at 40 degrees C and 75% relative humidity, the most demanding of the four ICH zones. India falls in Zone IVb. Pharmaceutical products sold in India must pass stability studies under these conditions, and the packaging must maintain its barrier properties throughout. Packaging that fails to hold its moisture barrier under Zone IVb conditions fails the stability test and blocks market authorisation.

Q: What is WVTR and how does it relate to pharmaceutical packaging?

WVTR is Water Vapour Transmission Rate: the amount of water vapour that passes through one square metre of packaging film per day. Lower WVTR means better moisture barrier. For pharmaceutical packaging in India, the laminate's WVTR must be validated against the formulation's moisture sensitivity and shelf life target under ICH Zone IVb conditions. Foil-laminated structures (PET/AL/PE) provide near-zero WVTR and are the benchmark for moisture-critical APIs.

Q: What are the mandatory label requirements for pharmaceutical packaging in India?

Under Rule 96 of the Drugs and Cosmetics Rules 1945, mandatory elements include: drug name and generic name, active ingredient composition, batch number, date of manufacture, expiry date, storage conditions, net quantity, manufacturer name and address, manufacturing licence number, and Schedule H/H1/X designation where applicable. From 2025, QR codes for traceability are mandatory for Schedule H, H1, and X drugs.

Q: Are flexible pouches compliant for pharmaceutical use in India?

Yes. Flexible pouches are used extensively for bulk pharmaceutical supply, institutional distribution, ORS sachets, nutraceuticals, and health supplements. Compliance depends on: pharmaceutical-grade BPA-free inner layer, laminate WVTR and OTR meeting the formulation's requirements, seal integrity validated at Zone IVb conditions, and all mandatory label information present on the pouch surface.

Q: What does tamper-evident packaging mean for pharmaceuticals?

Tamper-evident packaging provides visible evidence of first access. For pouches, a heat-sealed top that can only be opened by tearing meets this requirement. A zipper-only closure does not qualify. The compliant design for multi-dose pharmaceutical pouches is dual closure: heat seal above the zipper for tamper evidence on first opening, with the zipper providing resealability for subsequent access.

Q: Do pharmaceutical manufacturers need to comply with EPR rules?

Yes. Pharmaceutical manufacturers using plastic flexible packaging must register on the CPCB EPR portal and meet annual recycling targets. From July 2025, all plastic pharmaceutical packaging must also carry a QR code incorporating the CPCB EPR registration number. This is separate from the CDSCO traceability QR code. See our guide to EPR compliance for ecommerce packaging in India for the full breakdown.

Q: What pouch size should I use for bulk pharmaceutical supply?

For institutional bulk supply, stand up pouches in 250g to 1 kg formats are standard. Three side seal pouches in 50g to 200g formats suit smaller clinical or retail pack sizes. The right size minimises headspace, reducing the air volume inside the sealed pack and thereby reducing the moisture and oxygen load the barrier film must manage over shelf life. Validate fill weight and headspace with a physical pack test before bulk ordering.

The Bottom Line

Pharmaceutical packaging pouches in India sit at the intersection of barrier science, regulatory compliance, and patient safety. The ICH Zone IVb requirement means the Indian market places higher demands on packaging moisture performance than most markets globally, and CDSCO enforcement, QR code mandates, and EPR obligations mean the regulatory compliance burden on manufacturers has grown significantly through 2025 and 2026.

The flexible pouch formats that meet these requirements are well-established: foil-laminated three side seal pouches for tablets, capsules, and powders; stand up pouches for bulk institutional supply; and nylon vacuum pouches for export-grade or high-value API packaging. What matters is specifying the right laminate structure, validating seal integrity under Zone IVb conditions, and ensuring every pack carries the full set of mandatory label information including QR codes.

Browse Three Side Seal Pouches on OnGoMart

Browse Stand Up Pouches on OnGoMart →